Alyeska Investment Group
AGIO icon

Alyeska Investment Group’s Agios Pharmaceuticals AGIO Stock Holding History

Alyeska Investment Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-146,514
Closed -$5.88M – 583
2025
Q3 		$5.88M Buy
+146,514
New +$5.51M 0.02% 440
2020
Q4 		– Sell
-139,132
Closed -$4.87M – 503
2020
Q3 		$4.87M Sell
139,132
-37,359
-21% -$1.64M 0.07% 267
2020
Q2 		$9.44M Buy
176,491
+82,939
+89% +$3.84M 0.14% 205
2020
Q1 		$3.32M Buy
93,552
+43,362
+86% +$2M 0.07% 227
2019
Q4 		$2.4M Sell
50,190
-28,561
-36% -$1.08M 0.03% 284
2019
Q3 		$2.55M Sell
78,751
-132,868
-63% -$5.5M 0.04% 274
2019
Q2 		$10.6M Buy
211,619
+54,501
+35% +$2.91M 0.14% 169
2019
Q1 		$10.6M Buy
157,118
+75,405
+92% +$4.39M 0.14% 167
2018
Q4 		$3.77M Buy
+81,713
New +$5.04M 0.05% 246

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Alyeska Investment Group's AGIO Position: Q4 2025 in Review

Alyeska Investment Group sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 146,514 shares — an estimated $5.88M sold.

Alyeska Investment Group first reported a position in AGIO in Q4 2018 and held it in 9 quarters. The position peaked at $10.6M in Q1 2019. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Alyeska Investment Group reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 146,514 Agios Pharmaceuticals shares in Q4 2025, an estimated $5.88M.
  • Alyeska Investment Group first reported a position in Agios Pharmaceuticals in Q4 2018 and held it in 9 quarters.
  • Alyeska Investment Group's Agios Pharmaceuticals position peaked at $10.6M in Q1 2019.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.